Bain Capital-backed Solid Biosciences rolls out IPO
Cambridge, Massachusetts-based Solid Biosciences, which is focused on treating Duchenne muscular dystrophy, has raised $125 million after pricing its IPO of over 7.8 million at $16 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “SLDB.” J.P. Morgan, Goldman Sachs and Leerink Partners are the lead underwriters. Solid Biosciences' pre-IPO backers include RA Capital Management, Bain Capital Life Sciences, RTW Investments, Foresite Capital, Cormorant Asset Management LLC, Perceptive Advisors and Janus Capital Management.
26 January 2018•3 mins read
